BioNTech to acquire CureVac in $1.25 billion all-stock deal

• click to rate

  Posted by Two Blokes Jun 12 - Filed in Stock - 6 views
  
  German biotech firm BioNTech said on Thursday it agreed to acquire domestic peer CureVac for about $1.25 billion worth of BioNTech shares to boost its work on new mRNA-based cancer treatments.